{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluticasone+propionate+250mcg%2FSalmeterol+50mcg", "query": { "intervention": "Fluticasone propionate 250mcg/Salmeterol 50mcg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluticasone+propionate+250mcg%2FSalmeterol+50mcg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T12:30:49.774Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01324362", "title": "GSK BHR Study (Sont - Second Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "FP 100mcg", "type": "DRUG" }, { "name": "FP 250mcg", "type": "DRUG" }, { "name": "FP 500mcg", "type": "DRUG" }, { "name": "FSC 100/50mcg", "type": "DRUG" }, { "name": "FSC 250/50mcg", "type": "DRUG" }, { "name": "FSC500/50mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 446, "start_date": "2003-01", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2016-09-01", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01324362" }, { "nct_id": "NCT00920543", "title": "GSK BHR Study (Sont)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "FP 100mcg", "type": "DRUG" }, { "name": "FP 500mcg", "type": "DRUG" }, { "name": "FP 250mcg", "type": "DRUG" }, { "name": "FSC 100/50mcg", "type": "DRUG" }, { "name": "FSC 250/50mcg", "type": "DRUG" }, { "name": "FSC 500/50mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 464, "start_date": "2003-02", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2016-09-01", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "Palmdale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00920543" }, { "nct_id": "NCT01475721", "title": "SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "ADVAIR 100/50mcg", "type": "DRUG" }, { "name": "ADVAIR 250/50mcg", "type": "DRUG" }, { "name": "ADVAIR 500/50mcg", "type": "DRUG" }, { "name": "FLOVENT 100mcg", "type": "DRUG" }, { "name": "FLOVENT 250mcg", "type": "DRUG" }, { "name": "FLOVENT 500mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 11751, "start_date": "2011-11-18", "completion_date": "2015-06-23", "has_results": true, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 350, "location_summary": "Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475721" }, { "nct_id": "NCT01772134", "title": "Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Umeclidinium bromide 62.5mcg", "type": "DRUG" }, { "name": "Umeclidinium bromide 125mcg", "type": "DRUG" }, { "name": "Fluticasone propionate 250mcg/Salmeterol 50mcg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 617, "start_date": "2013-01-01", "completion_date": "2013-07-22", "has_results": true, "last_update_posted_date": "2018-01-29", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 13, "location_summary": "Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01772134" }, { "nct_id": "NCT01772147", "title": "Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Umeclidinium bromide 62.5mcg", "type": "DRUG" }, { "name": "Umeclidinium bromide 125mcg", "type": "DRUG" }, { "name": "Fluticasone propionate 250mcg/Salmeterol 50mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 608, "start_date": "2013-01", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 17, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 13 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01772147" }, { "nct_id": "NCT00568347", "title": "Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COPD" ], "interventions": [ { "name": "fluticasone 100mcg/ salmeterol 50mcg", "type": "DRUG" }, { "name": "fluticasone 250/salmeterol 50", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" }, { "name": "salmeterol and fluticasone propionate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arthur F Gelb MD", "sponsor_class": "INDIV", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "20 Years to 85 Years" }, "enrollment_count": 39, "start_date": "2006-01", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00568347" }, { "nct_id": "NCT01323621", "title": "Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg", "type": "DRUG" }, { "name": "Fluticasone Propionate 250mcg / salmeterol 50mcg", "type": "DRUG" }, { "name": "Double-dummy placebo", "type": "DRUG" }, { "name": "Salbutamol as needed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 512, "start_date": "2011-03-18", "completion_date": "2012-01-24", "has_results": true, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 13, "location_summary": "Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Riverside", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323621" }, { "nct_id": "NCT02826343", "title": "New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Xenon129 MRI imaging", "type": "DRUG" }, { "name": "Gadolinium MRI", "type": "DRUG" }, { "name": "Advair (250mcg/50mcg) one puff twice a day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2016-05-01", "completion_date": "2018-06-15", "has_results": false, "last_update_posted_date": "2020-11-04", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02826343" }, { "nct_id": "NCT01323634", "title": "Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg", "type": "DRUG" }, { "name": "Fluticasone Propionate 250mcg/ salmeterol 50mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 519, "start_date": "2011-03-18", "completion_date": "2011-12-14", "has_results": true, "last_update_posted_date": "2017-11-08", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 12, "location_summary": "Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323634" }, { "nct_id": "NCT01462344", "title": "6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "ADVAIR 100/50mcg", "type": "DRUG" }, { "name": "ADVAIR 250/50mcg", "type": "DRUG" }, { "name": "FLOVENT 100mcg", "type": "DRUG" }, { "name": "FLOVENT 250mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "4 Years to 11 Years" }, "enrollment_count": 6250, "start_date": "2011-11-17", "completion_date": "2015-11-03", "has_results": true, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-10-04T12:30:49.774Z", "location_count": 267, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 208 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Scottsboro", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01462344" } ] }